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Summary
Background VKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variability 
for individuals of African descent than for those of European or Asian descent. We aimed to identify additional 
variants contributing to warfarin dose requirements in African Americans.
Methods We did a genome-wide association study of discovery and replication cohorts. Samples from African-
American adults (aged ≥18 years) who were taking a stable maintenance dose of warfarin were obtained at International 
Warfarin Pharmacogenetics Consortium (IWPC) sites and the University of Alabama at Birmingham (Birmingham, 
AL, USA). Patients enrolled at IWPC sites but who were not used for discovery made up the independent replication 
cohort. All participants were genotyped. We did a stepwise conditional analysis, conditioning fi rst for VKORC1 
–1639G→A, followed by the composite genotype of CYP2C9*2 and CYP2C9*3. We prespecifi ed a genome-wide 
signifi cance threshold of p<5×10–⁸ in the discovery cohort and p<0·0038 in the replication cohort.
Findings The discovery cohort contained 533 participants and the replication cohort 432 participants. After the 
prespecifi ed conditioning in the discovery cohort, we identifi ed an association between a novel single nucleotide 
polymorphism in the CYP2C cluster on chromosome 10 (rs12777823) and warfarin dose requirement that reached 
genome-wide signifi cance (p=1·51×10–⁸). This association was confi rmed in the replication cohort (p=5·04×10–⁵); 
analysis of the two cohorts together produced a p value of 4·5×10–¹². Individuals heterozygous for the rs12777823 A 
allele need a dose reduction of 6·92 mg/week and those homozygous 9·34 mg/week. Regression analysis showed 
that the inclusion of rs12777823 signifi cantly improves warfarin dose variability explained by the IWPC dosing 
algorithm (21% relative improvement).
Interpretation A novel CYP2C single nucleotide polymorphism exerts a clinically relevant eff ect on warfarin dose in 
African Americans, independent of CYP2C9*2 and CYP2C9*3. Incorporation of this variant into pharmacogenetic 
dosing algorithms could improve warfarin dose prediction in this population.
Funding National Institutes of Health, American Heart Association, Howard Hughes Medical Institute, Wisconsin 
Network for Health Research, and the Wellcome Trust.
Introduction
Warfarin is the most widely prescribed oral anticoagulant 
in the USA, with more than 35 million prescriptions in 
2011.1 Complicated by a narrow thera peutic index, warfarin 
contributes to 33% of hospital admissions related to 
adverse drug events in individuals aged at least 65 years 
from the USA.2 Rapid and predictable therapeutic anti-
coagulation is diffi  cult because dose requirements vary 
substantially between patients, but is crucial for safe and 
eff ective treatment.3,4
Dose variability is aff ected by single nucleotide 
polymorphisms (SNPs) in genes encoding cytochrome 
P450 2C9 (CYP2C9), which metabolises the S-enantiomer 
of warfarin (more active than the R-enantiomer), and 
vitamin K epoxide reductase complex 1 (VKORC1), which 
is the target enzyme for the drug. Both candidate gene 
studies and genome-wide association studies (GWAS) 
have consistently shown that VKORC1 and CYP2C9 
genotypes explain up to 30% of the total variability in 
warfarin dose requirements in people of European or 
Asian origin.5–12 The International Warfarin Pharma-
cogenetics Consortium (IWPC) has shown that the 
VKORC1 –1639G→A SNP (rs9923231), CYP2C9*2 
(rs1799853), and CYP2C9*3 (rs1057910) can be used with 
clinical variables to predict warfarin dose.13,14
Unfortunately, these commonly studied genetic vari-
ants explain substantially less variability in individuals of 
African descent than in those of European or Asian 
origin.5,13,14 African Americans have been absent in 
previous warfarin GWAS. Importantly, the genomes of 
people of African ancestry have decreased linkage 
disequilibrium and increased diversity.15 Therefore, we 
aimed to identify novel variants contributing to warfarin 
dose requirements in African Americans.
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Methods
Study population
We did a GWAS of two study samples: one from IWPC 
sites across the USA and one from the University of 
Alabama at Birmingham (UAB; Birmingham, AL, USA). 
Together, these samples made up the discovery cohort. 
Patients enrolled in IWPC sites, but who were not used 
for discovery (enrolled at local site after samples from 
that site were sent for genotyping or their local site did 
not join IWPC until after IWPC samples were sent for 
genotyping), made up an independent replication cohort. 
All study participants (discovery and replication cohorts) 
were adults (aged ≥18 years) of self-reported African 
ancestry who were taking a stable maintenance dose of 
warfarin, and for whom clinical and demographic data 
had been obtained as previously reported.5,13 Defi nitions 
of stable dose varied between sites (appendix), but most 
sites insisted that patients had to have been on a stable 
dose for at least three consecutive clinic visits, which is 
indicative of the maintenance phase of warfarin 
treatment after initial stable dosing has been achieved. 
Patients provided  a DNA sample (whole-blood, saliva, or 
mouthwash sample). All participants gave written 
informed consent to participate, and all protocols were 
approved by local institutional review boards.
Procedures
For the IWPC samples, data curation and quality control 
procedures were as described previously.13,14 Data for 
several variables were obtained for participants from 
IWPC sites in the discovery cohort (appendix). These 
individuals were genotyped with the Illumina 610 Quad 
BeadChip (Illumina, San Diego, CA, USA) at the RIKEN 
Center for Genomic Medicine (Yokohama, Japan).
Information about demographic and clinical variables 
was obtained for the UAB study sample as previously 
described.5 Participants from UAB were genotyped at the 
University of Washington’s Department of Genome 
Sciences (Seattle, WA, USA) with the Illumina 
Human1M-Duo 3.0 (Illumina, San Diego, CA, USA). 
SNPs previously associated with warfarin dose were 
genotyped independently (ie, via single SNP genotyping 
and at local institutions) in both datasets.
In the replication cohort, samples were tested for a 
genome-wide signifi cant signal (p<5×10–⁸). To ensure 
important signals approaching genome-wide signifi -
cance were not missed, we identifi ed an additional 
12 SNPs with 10–⁵>p>5×10–⁸ as being of interest that were 
also tested in the replication cohort. IWPC repli cation 
samples were genotyped at Vanderbilt University’s DNA 
Resources Core (Nashville, TN, USA) with the Sequenom 
(San Diego, CA, USA) platform, and UAB replication 
samples at the University of Washington (Seattle, WA, 
USA) by Sanger sequencing.
To provide insight into potential functional mechan-
isms of an identifi ed SNP, we assessed the pharma-
cokinetics of warfarin in an independent cohort of 
60 African Americans on stable warfarin doses, as previ-
ously described.16 Briefl y, venous blood was obtained 
12–16 h after a warfarin dose. Warfarin enantiomer 
concentrations were established by a chiral high-
performance liquid chromatography-based method, and 
the oral clearance of both enantiomers, corrected for 
body surface area, was calculated.17 Warfarin is almost 
exclu sively cleared by liver metabolism, thus oral clear-
ance approximates the hepatic metabolism of warfarin.
The phenotypic data and a restricted genotypic data-
set (eg, VKORC1, CYP2C9, CYP4F2, and rs12777823) are 
accessible for download at PharmGKB. The IWPC 
GWAS data are made available under the IWPC Data 
Usage Agreement and can be accessed at PharmGKB.
Statistical analysis
Conventional GWAS quality control procedures were 
undertaken, such as checks for sex mismatches, identity 
by descent testing, deviation from Hardy–Weinberg 
Equilibrium, and SNP and sample exclusions on the 
basis of call rates (appendix).
Imputation of additional SNPs was done with hidden 
Markov models via MACH (version 1.0),18 on the basis of 
HapMap Phase 2 Release 22 data (appendix). The quality 
metric (r²) was calculated for all imputed SNPs; no SNPs 
reported here had a value of less than 0·8.
Global estimates of ancestry (appendix) were estab lished 
by the fi rst and second principal components, with the fi rst 
principal component used as a global estimate of African 
ancestry. All covariates obtained in each dataset (including 
drugs; appendix) and the fi rst ten principal components 
obtained through EIGENSTRAT (version 4.2)19 were tested 
as single covariates in a PLINK (version 1.07) additive 
model analysis for association with stable warfarin dose. 
Mean height and weight by sex were used for participants 
missing these variables in the IWPC cohort.
For all analyses, the primary phenotype (weekly stable 
warfarin dose) was log transformed to give a normal 
distribution. We excluded individuals missing data for 
non-genetic covariates associated with warfarin dose. 
For the discovery cohort, GWAS analysis was done in 
PLINK with a linear regression additive genetic model, 
by use of covariates signifi cantly associated with stable 
warfarin dose. We combined GWAS results for the 
IWPC and UAB study samples with fi xed eff ects meta-
analysis. We used the same quality-control procedures 
and analysis approaches in the replication cohort.
Previous warfarin GWAS in individuals of European 
and Asian ancestry emphasised the importance of con-
ditioning analyses for the well recognised VKORC1 and 
CYP2C9 SNPs.10,12,20 Therefore, a-priori analysis plans also 
included a stepwise conditional analysis, con ditioning 
fi rst for VKORC1 –1639G→A, followed by the composite 
genotype (presence or absence of a variant allele) of 
CYP2C9*2 and CYP2C9*3 (appendix).
We prespecifi ed a genome-wide signifi cance threshold 
of p<5×10–⁸ for the discovery cohort. For the replication 
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cohort, we defi ned the signifi cance level on the basis of 
the number of samples tested (13 SNPs). Therefore, 
signifi cant replication was defi ned as a Bonferroni-
corrected p value of less than 0·05/13 or 0·0038.
Additionally, we looked at a previous GWAS of 
individuals of European and Asian ancestry9,10,12 to identify 
any association between the identifi ed SNP and warfarin 
dose. We tested the SNP in a previously described 
Egyptian cohort.21
We modelled the residual dose (actual dose minus 
predicted IWPC dose) with linear regression, with 
genotypes of a replicated SNP as covariates in 
participants in the discovery cohort for whom complete 
data were available for calculation of warfarin dose with 
the IWPC algorithm. We tested the diff erence between 
the models (with and without rs12777823 as a covariate) 
by ANOVA. All statistical analyses were done with R 
(version 2.10.1).
Pharmacokinetic variables were compared between 
genotype groups by ANOVA, and between the GG 
genotype and both the AA and AG genotypes by the 
one-sided Student’s unpaired t test, with the expected 
direction defi ned by the data from the GWAS.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. MAP, LHC, NAL, NJC, RBA, TEK, 
and JAJ had complete access to the data, and JAJ had fi nal 
responsibility for the decision to submit for publication.
Results
For the IWPC study sample, eight institutions con-
tributed genetic and clinical data for 345 African-
American individuals, although 18 were subsequently 
excluded because of missing data or quality-control 
issues. The UAB study sample consisted of 206 African 
Americans; no participant was excluded from analysis 
because of quality control issues. Therefore, the discovery 
cohort contained 533 participants after quality control 
(table 1). The replication cohort consisted of 432 African 
Americans enrolled from six IWPC sites, including UAB 
(table 1; appendix).
Participants in both the IWPC and UAB cohorts 
clustered between the HapMap CEU (northern and 
western European ancestry) and YRI (African ancestry) 
samples, as was expected (appendix). Mean proportion of 
African ancestry in the discovery cohort was 85% (SD 9%) 
in participants from IWPC sites and 86% (8%) from UAB. 
The proportion of African ancestry was not associated 
with warfarin dose in participants from IWPC sites 
(p=0·08) or from UAB (p=0·944). 557 286 SNPs passed 
quality-control checks in the IWPC samples (mean call 
rate 99·96%) and 950 007 in the UAB samples (99·95%).
Age, weight, height, aspirin use, and amiodarone use 
were associated with warfarin dose in the discovery cohort 
(p<0·05 for all in both IWPC and UAB samples; appendix). 
A glomerular fi ltration rate of less than 30 mL/min in UAB 
samples was also associated with warfarin dose (p<0·05).
None of the SNPs reported here that were associated 
with stable warfarin dose signifi cantly deviated from 
Hardy–Weinberg equilibrium. SNPs on chromo some 16 
reached genome-wide sig nifi cance, including VKORC1 
–1639G→A (rs9923231; p=2·08×10–⁹; fi gure 1, appendix). 
Associations with SNPs in linkage dis equilibrium with 
rs9923231 on chromo some 16 were also signifi cant 
(appendix).
After the prespecifi ed conditioning on the VKORC1 
locus, CYP2C9*2, and CYP2C9*3, the most signifi cant 
SNP association with warfarin dose was rs12777823 on 
chromosome 10 (p=1·51×10–⁸; fi gure 1, appendix). The 
minor allele frequency was about 25% in the discovery 
cohort (appendix). Other top signals after conditioning 
are shown in the appendix.
The SNP that achieved genome-wide signifi cance in the 
discovery cohort after conditioning (rs12777823) was also 
signifi cantly associated with stable warfarin dose in the 
replication cohort after conditioning (p=5·04×10–⁵; 
fi gure 2, appendix). This p value is well below the 
threshold of 0·0038 that had been defi ned for signifi cant 
replication. A combined analysis of the discovery and 
Discovery cohort Replication 
cohort (n=432)
International 
Warfarin 
Pharmacogenetics 
Consortium (n=327)
University of 
Alabama at 
Birmingham 
(n=206)
Stable warfarin dose (mg/wk) 45·6 (18·6) 42·2 (18·4) 45·7 (23·8)
International normalised ratio 2·46 (0·44) 2·41 (0·40) 2·48 (0·31)
Age (years) 57·1 (14·8) 59·1 (15·3) 58·6 (16·0)
Height (cm) 169·4 (10·1) 170·9 (10·5) 170·4 (27·2)
Weight (kg) 94·4 (10·1) 89·6 (22·9) 93·5 (27·8)
Sex
Male 121 (37%) 92 (45%) 168 (39%)
Female 206 (63%) 114 (55%) 264 (61%)
Primary warfarin indication*
Pulmonary embolism or deep vein thrombosis 153 (47%) 97 (47%) 186 (59%)
Atrial fi brillation or fl utter 81 (25%) 68 (33%) 67 (21%)
Cardiomyopathy or left ventricle dilation 5 (2%) 0 0
Heart valve replacement 26 (8%) 0 7 (2%)
Stroke 28 (9%) 21 (10%) 29 (9%)
Other 34 (10%) 20 (10%) 27 (9%)
Current smoker 53 (16%) 34 (17%) NA
Amiodarone use 16 (5%) 7 (3%) 21 (5%)
Aspirin use 92 (28%) 93 (45%) 149 (34%)
Genotype†
CYP2C9*2 12 (2%) 6 (1%) 19 (2%)
CYP2C9*3 5 (1%) 6 (1%) 13 (2%)
VKORC1 –1639G→A 59 (10%) 38 (10%) 77 (11%)
Data are mean (SD) or n (%). NA=not available. *Primary indication was not available for 116 individuals in the replication 
cohort. †Reported as number of people carrying one or two variant alleles; percentage is minor allele frequency. 
Table 1: Baseline characteristics
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replication cohorts for rs12777823 leads to a combined 
p value of 4·5×10–¹². None of the 12 SNPs of interest 
were associated with stable warfarin dose (appendix). 
rs12777823 was also not associated with warfarin dose in 
individuals of European and Japanese ancestry, or 
Egyptian individuals (data not shown).
The IWPC warfarin dosing equation is less predictive 
for African Americans than for other populations.13 We 
modelled the residual dose with linear regression in 
504 participants from the discovery cohort. Addition of 
rs12777823 genotype to the IWPC algorithm improved 
the ability to predict actual therapeutic warfarin dose 
with the IWPC algorithm by an absolute 5% (relative 
21%; table 2). Indi viduals heterozygous or homozygous 
for the rs12777823 A allele have reduced stable warfarin 
doses (table 2).
In the independent cohort of 60 African Americans, 
the hepatic metabolism of the S-enantiomer of warfarin 
(as estimated by oral clearance) diff ered signifi cantly 
with rs12777823 genotype (table 3). Additionally, the ratio 
of the R-enantiomer and S-enantiomer diff ered signifi -
cantly by rs12777823 genotype, consistent with genotypic 
diff erences in metabolism of the S-enantiomer, but not 
of the R-enantiomer (table 3).
CYP2C9*2 and CYP2C9*3 occurred at low frequency 
(table 1) and were not signifi cantly associated with 
warfarin dose variability (CYP2C9*2 nominal p=0·834; 
CYP2C9*3 nominal p=0·023). Of the CYP2C9 non-
synonymous polymorphisms specifi c to individuals of 
African descent, only CYP2C9*11 was imputed in the 
meta-analysis and had a signifi cant association with 
warfarin dose (p=0·0001). The CYP2C9*5, CYP2C9*6, 
and CYP2C9*8 alleles were not included on the GWAS 
arrays and could not be imputed. Analyses with add-
itional CYP2C9 alleles (eg, CYP2C9*5, CYP2C9*6, and 
CYP2C9*8) had low power, because few participants were 
genotyped for these alleles independent of the GWAS. 
Notably, rs12777823 is in low linkage disequilibrium with 
CYP2C9*2, CYP2C9*3, and CYP2C9*11 (all r²<0·05), on 
the basis of the imputed genotypes for these alleles in the 
GWAS cohorts. Additionally, on the basis of participants 
independently genotyped for CYP2C9*5, CYP2C9*6, and 
CYP2C9*8, rs12777823 is also in low linkage dis-
equilibrium with these SNPs (all r²<0·10), suggesting 
that the rs12777823 signal is independent of previously 
studied CYP2C9 polymorphisms. The CYP4F2 Val433Met 
variant (rs2108622) that has been previously associated 
with warfarin dose in those of European and Asian 
descent10,12 was not associated with warfarin dose in this 
study (p=0·07).
Discussion
Our results show that VKORC1 genotype is the primary 
genetic determinant of variability in warfarin dose 
require ments in African Americans, which is consis-
tent with previous GWAS data from European and 
Japanese populations.9,10,12 After adjustment for VKORC1 
–1639G→A, CYP2C9*2, and CYP2C9*3, we identifi ed a 
novel asso ciation between rs12777823 and warfarin dose 
variability; we replicated this fi nding in an independent 
African American cohort.
Figure 1: Manhattan plots showing associations between single nucleotide polymorphisms and stable 
warfarin dose in the discovery cohort
(A) Without and (B) with prespecifi ed conditioning. The top line shows p=5×10⁸. Green points indicate 
genome-wide signifi cant regions.
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In the context of other genotypes and clinical factors in 
the IWPC model, the rs12777823 genotype was asso ciated 
with a reduction in dose of almost 7 mg/week in hetero-
zygotes and of 9 mg/week in homozygotes—an eff ect 
similar to that of the CYP2C9*2 allele in the IWPC dosing 
algorithm.13 Thus, the eff ect is consistent with a poly-
morphism that is well accepted to be clinically relevant for 
individuals. The eff ect is also important at a population 
level, because of both the eff ect size and the frequency of 
the polymorphism. Specifi cally, rs12777823 explains 5% of 
the variability in warfarin dose in African Americans, 
which is consistent with the variability explained by 
CYP2C9*2 and CYP2C9*3 in individuals of European 
ancestry,8 and greatly exceeds the variability explained by 
CYP2C9*2 and CYP2C9*3 in African Americans (1–2%).5,22
Our fi ndings have important implications for pre diction 
of warfarin maintenance dose in individuals of African 
ancestry, for whom current warfarin pharmaco genetic 
algorithms are less predictive.13,14 On the basis of our data, 
the IWPC algorithm could be used to estimate warfarin 
dose, and then the rs12777823 variant in African Americans 
could be accounted for with dose reductions (panel). 
Further improvement in dose estimation might eventually 
be possible for African Americans when additional SNPs 
specifi c to individuals with African ancestry are identifi ed.
rs12777823 is located within the CYP2C gene cluster, 
upstream from CYP2C18 on chromosome 10q23, and 
includes the CYP2C9, CYP2C8, CYP2C18, and CYP2C19 
genes. In a GWAS of clopidogrel antiplatelet eff ect in 
Amish individuals,27 rs12777823 was the strongest sig-
nal, although it was in strong linkage disequilibrium 
(r²=0·87) with CYP2C19*2 (rs4244285), which produces a 
non-functional truncated CYP2C19 protein and is 
believed to be the causative variant. We reported low 
linkage disequilibrium (r²=0·5) between rs12777823 and 
CYP2C19*2, and the association between warfarin dose 
requirements and CYP2C19*2 was not signifi cant at the 
genome-wide level and was absent when conditioned on 
rs12777823. Therefore, the eff ect of rs12777823 in African 
Americans is probably independent of CYP2C19*2.
The functional basis for the reported association 
between warfarin dose and rs12777823 is unknown, 
but the pharmacokinetic data indicate an eff ect on 
metabolism of the S-enantiomer. The S-enantiomer is 
metabolised primarily by CYP2C9, and the stereoselective 
nature of the genetic association suggests rs12777823 
aff ects CYP2C9 activity. Importantly, the low linkage 
disequilibrium between this SNP and other known 
functional SNPs in CYP2C9 suggest that it has an inde-
pendent and novel genetic eff ect on CYP2C9 metabolism, 
which could have clinically important implications for 
many other drugs that are CYP2C9 substrates.
rs12777823 is common in African Americans: in our 
study, the minor allele frequency was 25% in both the 
discovery and replication cohorts. Although common in 
European (minor allele frequency 14%) and Japanese 
(32%) populations, rs12777823 did not have a signifi cant 
Panel: Research in context
Systematic review
We searched PubMed for reports of studies and meta-analyses published in any language 
before Dec 1, 2012. We used the search terms “warfarin” and “genome wide association 
study”. We identifi ed three genome-wide association studies of warfarin dose 
requirement9,10,12 and one of acenocoumarol.20 All previous studies were done in either 
European or Asian populations. They all showed that that VKORC1 –1639G→A (rs9923231), 
CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), and CYP4F2 (rs2108622) are the main 
genetic determinants of drug dose. The study of acenocoumarol20 identifi ed a single 
nucleotide polymorphism (SNP) upstream of CYP2C18, although it did not reach 
genome-wide signifi cance after conditioning for CYP2C9*2 and CYP2C9*3. To identify 
previous studies testing genetic variation associated with warfarin dose requirements in 
African Americans, we did another search of PubMed with the same date criteria and no 
language restrictions, but used the search terms “warfarin” and “African American”. We 
identifi ed fi ve studies,22–26 all of which used a candidate-gene approach.
Interpretation
As far as we are aware, ours is the fi rst genome-wide association study to investigate 
warfarin dose requirements in African Americans. Our results identifi ed a SNP upstream of 
CYP2C18, rs12777823, that is signifi cantly associated with warfarin dose requirement in 
African Americans and is independent of previous associations with VKORC1 and CYP2C9. 
Patients carrying this SNP have a signifi cantly lower stable dose of warfarin than do those 
without this variant, and the addition of this SNP improved the International Warfarin 
Pharmacogenetics Consortium algorithm by 21%. We have also shown that this SNP 
signifi cantly alters warfarin clearance. To our knowledge, no other studies of warfarin dose 
requirement have identifi ed this SNP.
Coeffi  cient* p value Adjusted 
model R²†
IWPC dosing equation 
Predicted Dose
·· <2×10¹⁶ 0·2193
rs12777823 AG –6·92 6·76×10⁶ ··
rs12777823 AA –9·34 0·00050 ··
IWPC dosing equation and 
rs1277823
·· 1·7×10–6 0·2666
IWPC=International Warfarin Pharmacogenetics Consortium. *Represents 
change in warfarin dose (mg/week). †Increase indicates increase in amount of 
variability explained.
Table 2: Eff ects of novel CYP2C variation on warfarin dose prediction 
with the IWPC dosing algorithm
AA (n=6) AG (n=24) GG (n=30)
Oral clearance of S-enantiomer 
(mL/min/m²)*
1·20 (0·69) 1·38 (0·48) 1·80 (0·83)
Plasma concentration ratio of 
R-enantiomer to S-enantiomer†
1·29 (0·50) 1·42 (0·43) 1·76 (0·68)
Data are mean (SD). Clearance values are normalised for body surface area. 
*p=0·042 for association between the three genotype groups (one-way ANOVA); 
p=0·049 for comparison between AA and GG genotypes, and p=0·016 for 
comparison between AG and GG genotypes (one-sided Student’s unpaired t test). 
†p=0·049 for association between the three genotype groups (one-way ANOVA); 
p=0·039 for comparison between AA and GG genotypes, and p=0·018 for 
comparison between AG and GG genotypes (one-sided Student’s unpaired t test).
Table 3: Pharmacokinetic parameters of warfarin R-enantiomer and 
S-enantiomer by rs12777823 genotype
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association with warfarin dose in previous GWAS,9,10,12 or 
when we interrogated the European and Japanese GWAS 
datasets for this SNP. Similarly, this SNP did not have an 
association with warfarin dose in about 200 individuals 
from Egypt. Collectively, these data suggest that the 
association in African Americans might not be due to 
rs12777823 itself, but a causal SNP in linkage dis-
equilibrium with rs12777823 in African Americans but 
not in other populations.
Although the CYP2C9*2 and CYP2C9*3 alleles con-
tribute to warfarin dose variability in populations of 
European descent,9,10 we recorded no genome-wide sig-
nifi cant association in the GWAS of African Americans. 
The low frequency of these alleles in this population 
might have contributed to this fi nding. 
GWAS has limitations because not all variants are 
interrogated—eg, a novel VKORC1 variant (rs61162043) 
identifi ed through resequencing and associated with 
increased warfarin dose requirements in African 
Americans22 is not captured on the GWAS genotyping 
platforms, nor is it in HapMap.28 CYP2C9*5, CYP2C9*6, 
CYP2C9*8, and CYP2C9*11 have been previously 
associated with warfarin dose variability,5,22,29 but were 
not included on the GWAS genotyping platforms; only 
CYP2C9*11 was available through imputation. Because 
few sites independently genotyped for these variants, 
we could not reliably estimate their contribution to 
warfarin dose requirements in our study. However, 
we could rule out the CYP2C9*2, CYP2C9*3, and 
CYP2C9*11 alleles as causes of the recorded association 
with the rs12777823 variant on the basis of conditional 
analyses and the com puted pairwise linkage dis-
equilibrium between these SNPs. Additionally, linkage 
disequilibrium between rs12777823 and CYP2C9*5, 
CYP2C9*6, and CYP2C9*8 was low in participants for 
whom these data were available.
Although use of new oral anticoagulants is expected to 
increase with time, warfarin will probably be widely 
used for the foreseeable future. A study reported in 
20121 suggested that dabigatran use has risen con sistently 
since its approval; 8·1% of oral anticoagulant prescriptions 
in the USA in late 2011 were for this drug. In Sweden, the 
proportion of prescriptions for oral anticoagulants that 
were for new drugs rose from 3·0% in 2011, to 4·7% in 
2012.30 Thus, although new oral anticoagulant use is 
increasing, warfarin remains the predominant oral anti-
coagulant. Additionally, in December, 2012, the US Food 
and Drugs Administration issued a safety notice that 
outlined that dabigatran is contraindicated in pa tients 
with mechanical heart valves, meaning new oral anti-
coagulants will not be used for all the indications for 
which warfarin is presently used.
Importantly, because of cost issues, warfarin will 
probably remain the mainstay oral anticoagulant for the 
uninsured or underinsured in the USA and individuals 
in developing countries—particularly in Africa—for 
many years to come. Therefore, identifi cation of a way 
to achieve therapeutic anticoagulation effi  ciently with 
warfarin is a priority. Pharmacogenetic warfarin dosing 
algorithms, such as the IWPC algorithm, could reduce 
the time needed to reach stable therapeutic dosing;8,13,31 
genotype-guided warfarin dosing better predicts warfarin 
main tenance dose than does standard dosing, and 
reduces out-of-range international normalised ratio 
values.31 Sec ondary analyses in a previous study31 also 
suggested the potential for improved outcomes via a 
pharmacogenetic approach. Randomised controlled 
trials are assessing the clinical utility of genotype-guided 
warfarin dosing.32,33 If the trials show benefi ts for pharma-
cogenetic approaches to warfarin, then future consensus 
guidelines will probably support warfarin pharmaco-
genetics in the clinical setting.
In conclusion, we have shown that VKORC1 is the 
major gene aff ecting warfarin dose variability in African 
Americans, with the CYP2C locus exerting infl uence 
independent of well known CYP2C9*2, CYP2C9*3, and 
CYP2C19*2 polymorphisms. Our fi ndings suggest that 
warfarin dose variability is aff ected by variants other than 
the well established VKORC1 and CYP2C9 ones in 
African Americans; these new variants could improve 
dose prediction in these individuals.
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